{"id":48655,"date":"2026-08-24T16:45:56","date_gmt":"2026-08-24T16:45:56","guid":{"rendered":"https:\/\/jornalboasnoticias.com.br\/home\/?p=48655"},"modified":"2026-08-24T16:45:56","modified_gmt":"2026-08-24T16:45:56","slug":"anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara","status":"publish","type":"post","link":"https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/","title":{"rendered":"Anvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara"},"content":{"rendered":"
\n

Terapia para Distrofia Muscular de Duchenne requer mais dados<\/p>\n<\/blockquote>\n

\"\"
\u00a9 Matheus Brasil\/Minist\u00e9rio da Sa\u00fade<\/figcaption><\/figure>\n

A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) e a empresa Roche comunicaram nesta segunda-feira (24)\u00a0o cancelamento do registro condicional do medicamento Elevidys\u00ae (delandistrogeno moxeparvoveque), a pedido da farmac\u00eautica. O registro condicional \u00e9 uma autoriza\u00e7\u00e3o tempor\u00e1ria de uso ou comercializa\u00e7\u00e3o de um produto no pa\u00eds.\u00a0A medida foi\u00a0publicada no Di\u00e1rio Oficial da Uni\u00e3o<\/a>.<\/p>\n

A interrup\u00e7\u00e3o foi adotada ap\u00f3s o entendimento de que os dados dispon\u00edveis at\u00e9 este momento sobre o Elevidys disponibilizados pela empresa fabricante n\u00e3o atendem aos requisitos de regula\u00e7\u00e3o necess\u00e1rios para manuten\u00e7\u00e3o do registro condicional no pa\u00eds.<\/p>\n

A Anvisa esclarece que o cancelamento do registro n\u00e3o altera as obriga\u00e7\u00f5es da empresa relacionadas ao acompanhamento dos pacientes previamente expostos ao medicamento nos estudos cl\u00ednicos e tamb\u00e9m nos programas existentes, incluindo os pacientes infantis brasileiros que receberam Elevidys\u00ae entre dezembro de 2024 e julho de 2025.<\/p>\n

O medicamento Elevidys \u00e9 indicado para pacientes com Distrofia Muscular de Duchenne (DMD). A doen\u00e7a gen\u00e9tica rara compromete progressivamente a musculatura \u2013 o que causa perda de massa muscular e fraqueza \u2013 devido ao impedimento da produ\u00e7\u00e3o adequada de distrofina, prote\u00edna considerada essencial para o funcionamento dos m\u00fasculos.<\/p>\n

Cronologia<\/h2>\n

O medicamento Elevidys\u00ae obteve registro condicional no Brasil em dezembro de 2024, em car\u00e1ter excepcional, com exig\u00eancia de apresenta\u00e7\u00e3o posterior de dados complementares sobre efic\u00e1cia e seguran\u00e7a no uso.<\/p>\n

No pa\u00eds, o Elevidys foi autorizado para tratamento da Distrofia Muscular de Duchenne (DMD) e em pacientes deambuladores, ou seja, em crian\u00e7as que ainda mant\u00eam a capacidade de andar de forma independente ou com aux\u00edlio, com idade entre 4 e 7 anos, e que atendiam a crit\u00e9rios cl\u00ednicos e laboratoriais espec\u00edficos \u00e0 \u00e9poca.<\/p>\n

Em julho de 2025, a comercializa\u00e7\u00e3o do produto no Brasil foi suspensa pela ag\u00eancia reguladora por meio da Resolu\u00e7\u00e3o (RE) 2.813\/2025, no aguardo de novos estudos e respostas da farmac\u00eautica para avaliar se os benef\u00edcios da medica\u00e7\u00e3o. A medida foi tomada em raz\u00e3o de relatos de casos fatais de insufici\u00eancia hep\u00e1tica aguda em pacientes tratados com o produto nos Estados Unidos.<\/p>\n

Em junho deste ano, em uma audi\u00eancia p\u00fablica na Comiss\u00e3o de Defesa dos Direitos das Pessoas com Defici\u00eancia da C\u00e2mara dos Deputados foram relatados estes alertas graves de seguran\u00e7a do produto.<\/p>\n

Desde a suspens\u00e3o, a Anvisa diz ter\u00a0encaminhado uma s\u00e9rie de exig\u00eancias formais \u00e0 empresa respons\u00e1vel pelo medicamento. Entre elas, est\u00e3o a apresenta\u00e7\u00e3o de dados consolidados de seguran\u00e7a, com foco em insufici\u00eancia hep\u00e1tica aguda.<\/p>\n

Segundo a Anvisa, nesse per\u00edodo, a Roche apresentou informa\u00e7\u00f5es complementares e manteve intera\u00e7\u00e3o cont\u00ednua com a Anvisa no contexto das obriga\u00e7\u00f5es regulat\u00f3rias associadas ao registro condicional.<\/p>\n

Em nota, a Roche diz que segue empenhada com o programa cl\u00ednico do Elevidys\u00ae e com a apresenta\u00e7\u00e3o das evid\u00eancias necess\u00e1rias.<\/p>\n

As duas partes tamb\u00e9m reafirmaram o compromisso com a sa\u00fade da popula\u00e7\u00e3o e decis\u00f5es regulat\u00f3rias fundamentadas nas melhores evid\u00eancias cient\u00edficas dispon\u00edveis, especialmente, de terapias avan\u00e7adas para o tratar doen\u00e7as graves e raras.<\/p>\n

Paralelamente, na \u00faltima quinta-feira (13), a Anvisa aprovou o registro de outro medicamento indicado para pacientes com DMD, o Duvyzat (givinostate). Os estudos cl\u00ednicos demonstraram que o novo produto \u00e9 capaz de retardar a progress\u00e3o da doen\u00e7a.<\/p>\n

Ag\u00eancia Brasil<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Terapia para Distrofia Muscular de Duchenne requer mais dados A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria<\/p>\n","protected":false},"author":3,"featured_media":48656,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-48655","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saude"],"yoast_head":"\nAnvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara - Jornal<\/title>\n<meta name=\"description\" content=\"Anvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara - Jornal\" \/>\n<meta property=\"og:description\" content=\"Anvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara\" \/>\n<meta property=\"og:url\" content=\"https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/\" \/>\n<meta property=\"og:site_name\" content=\"Jornal\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/boasnoticiasjornal\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-24T16:45:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/jornalboasnoticias.com.br\/home\/wp-content\/uploads\/2026\/08\/captura_de_tela_2026-08-24_133043_copy.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1170\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Luiz Carlos da Cruz\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luiz Carlos da Cruz\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\\\/\"},\"author\":{\"name\":\"Luiz Carlos da Cruz\",\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/#\\\/schema\\\/person\\\/75f9ebde398c998c166475fb446bda62\"},\"headline\":\"Anvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara\",\"datePublished\":\"2026-08-24T16:45:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\\\/\"},\"wordCount\":617,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/captura_de_tela_2026-08-24_133043_copy.webp\",\"articleSection\":[\"SA\u00daDE\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\\\/\",\"url\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\\\/\",\"name\":\"Anvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara - Jornal\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/captura_de_tela_2026-08-24_133043_copy.webp\",\"datePublished\":\"2026-08-24T16:45:56+00:00\",\"description\":\"Anvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\\\/#primaryimage\",\"url\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/captura_de_tela_2026-08-24_133043_copy.webp\",\"contentUrl\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/captura_de_tela_2026-08-24_133043_copy.webp\",\"width\":1170,\"height\":700,\"caption\":\"\u00a9 Matheus Brasil\\\/Minist\u00e9rio da Sa\u00fade\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/#website\",\"url\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/\",\"name\":\"Jornal Boas Not\u00edcias\",\"description\":\"Boas not\u00edcias\",\"publisher\":{\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/#organization\",\"name\":\"Coq Editora Ltda\",\"alternateName\":\"Jornal Boas Noticias\",\"url\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/cropped-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/cropped-logo.jpg\",\"width\":290,\"height\":142,\"caption\":\"Coq Editora Ltda\"},\"image\":{\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/boasnoticiasjornal\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/#\\\/schema\\\/person\\\/75f9ebde398c998c166475fb446bda62\",\"name\":\"Luiz Carlos da Cruz\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e6f4f45301b6cb8572f7b076572e8ac11c1db80e805d8c8d0858cf286ce3ac3b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e6f4f45301b6cb8572f7b076572e8ac11c1db80e805d8c8d0858cf286ce3ac3b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e6f4f45301b6cb8572f7b076572e8ac11c1db80e805d8c8d0858cf286ce3ac3b?s=96&d=mm&r=g\",\"caption\":\"Luiz Carlos da Cruz\"},\"url\":\"https:\\\/\\\/jornalboasnoticias.com.br\\\/home\\\/author\\\/luiz-carlos-da-cruz\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara - Jornal","description":"Anvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/","og_locale":"pt_BR","og_type":"article","og_title":"Anvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara - Jornal","og_description":"Anvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara","og_url":"https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/","og_site_name":"Jornal","article_publisher":"https:\/\/www.facebook.com\/boasnoticiasjornal","article_published_time":"2026-08-24T16:45:56+00:00","og_image":[{"width":1170,"height":700,"url":"https:\/\/jornalboasnoticias.com.br\/home\/wp-content\/uploads\/2026\/08\/captura_de_tela_2026-08-24_133043_copy.webp","type":"image\/webp"}],"author":"Luiz Carlos da Cruz","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Luiz Carlos da Cruz","Est. tempo de leitura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/#article","isPartOf":{"@id":"https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/"},"author":{"name":"Luiz Carlos da Cruz","@id":"https:\/\/jornalboasnoticias.com.br\/home\/#\/schema\/person\/75f9ebde398c998c166475fb446bda62"},"headline":"Anvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara","datePublished":"2026-08-24T16:45:56+00:00","mainEntityOfPage":{"@id":"https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/"},"wordCount":617,"commentCount":0,"publisher":{"@id":"https:\/\/jornalboasnoticias.com.br\/home\/#organization"},"image":{"@id":"https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/#primaryimage"},"thumbnailUrl":"https:\/\/jornalboasnoticias.com.br\/home\/wp-content\/uploads\/2026\/08\/captura_de_tela_2026-08-24_133043_copy.webp","articleSection":["SA\u00daDE"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/","url":"https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/","name":"Anvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara - Jornal","isPartOf":{"@id":"https:\/\/jornalboasnoticias.com.br\/home\/#website"},"primaryImageOfPage":{"@id":"https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/#primaryimage"},"image":{"@id":"https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/#primaryimage"},"thumbnailUrl":"https:\/\/jornalboasnoticias.com.br\/home\/wp-content\/uploads\/2026\/08\/captura_de_tela_2026-08-24_133043_copy.webp","datePublished":"2026-08-24T16:45:56+00:00","description":"Anvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara","breadcrumb":{"@id":"https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/#primaryimage","url":"https:\/\/jornalboasnoticias.com.br\/home\/wp-content\/uploads\/2026\/08\/captura_de_tela_2026-08-24_133043_copy.webp","contentUrl":"https:\/\/jornalboasnoticias.com.br\/home\/wp-content\/uploads\/2026\/08\/captura_de_tela_2026-08-24_133043_copy.webp","width":1170,"height":700,"caption":"\u00a9 Matheus Brasil\/Minist\u00e9rio da Sa\u00fade"},{"@type":"BreadcrumbList","@id":"https:\/\/jornalboasnoticias.com.br\/home\/anvisa-e-roche-cancelam-registro-de-elevidys-para-doenca-rara\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/jornalboasnoticias.com.br\/home\/"},{"@type":"ListItem","position":2,"name":"Anvisa e Roche cancelam registro de Elevidys para doen\u00e7a rara"}]},{"@type":"WebSite","@id":"https:\/\/jornalboasnoticias.com.br\/home\/#website","url":"https:\/\/jornalboasnoticias.com.br\/home\/","name":"Jornal Boas Not\u00edcias","description":"Boas not\u00edcias","publisher":{"@id":"https:\/\/jornalboasnoticias.com.br\/home\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/jornalboasnoticias.com.br\/home\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/jornalboasnoticias.com.br\/home\/#organization","name":"Coq Editora Ltda","alternateName":"Jornal Boas Noticias","url":"https:\/\/jornalboasnoticias.com.br\/home\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/jornalboasnoticias.com.br\/home\/#\/schema\/logo\/image\/","url":"https:\/\/jornalboasnoticias.com.br\/home\/wp-content\/uploads\/2024\/07\/cropped-logo.jpg","contentUrl":"https:\/\/jornalboasnoticias.com.br\/home\/wp-content\/uploads\/2024\/07\/cropped-logo.jpg","width":290,"height":142,"caption":"Coq Editora Ltda"},"image":{"@id":"https:\/\/jornalboasnoticias.com.br\/home\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/boasnoticiasjornal"]},{"@type":"Person","@id":"https:\/\/jornalboasnoticias.com.br\/home\/#\/schema\/person\/75f9ebde398c998c166475fb446bda62","name":"Luiz Carlos da Cruz","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/e6f4f45301b6cb8572f7b076572e8ac11c1db80e805d8c8d0858cf286ce3ac3b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e6f4f45301b6cb8572f7b076572e8ac11c1db80e805d8c8d0858cf286ce3ac3b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e6f4f45301b6cb8572f7b076572e8ac11c1db80e805d8c8d0858cf286ce3ac3b?s=96&d=mm&r=g","caption":"Luiz Carlos da Cruz"},"url":"https:\/\/jornalboasnoticias.com.br\/home\/author\/luiz-carlos-da-cruz\/"}]}},"_links":{"self":[{"href":"https:\/\/jornalboasnoticias.com.br\/home\/wp-json\/wp\/v2\/posts\/48655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jornalboasnoticias.com.br\/home\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jornalboasnoticias.com.br\/home\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jornalboasnoticias.com.br\/home\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/jornalboasnoticias.com.br\/home\/wp-json\/wp\/v2\/comments?post=48655"}],"version-history":[{"count":1,"href":"https:\/\/jornalboasnoticias.com.br\/home\/wp-json\/wp\/v2\/posts\/48655\/revisions"}],"predecessor-version":[{"id":48657,"href":"https:\/\/jornalboasnoticias.com.br\/home\/wp-json\/wp\/v2\/posts\/48655\/revisions\/48657"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/jornalboasnoticias.com.br\/home\/wp-json\/wp\/v2\/media\/48656"}],"wp:attachment":[{"href":"https:\/\/jornalboasnoticias.com.br\/home\/wp-json\/wp\/v2\/media?parent=48655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jornalboasnoticias.com.br\/home\/wp-json\/wp\/v2\/categories?post=48655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jornalboasnoticias.com.br\/home\/wp-json\/wp\/v2\/tags?post=48655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}